IPP Bureau
Jubilant Ingrevia appoints Kailash Ukhade as VP – Projects
By IPP Bureau - July 14, 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Moderna receives USFDA approval for Covid-19 vaccine ‘Spikevax’
By IPP Bureau - July 13, 2025
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Evonik opens new medical device center in Shanghai
By IPP Bureau - July 12, 2025
The company’s largest center for medical device applications, serving the entire Asian market
DKSH and Bayer partner across multiple markets in Southeast Asia
By IPP Bureau - July 12, 2025
Panacea Biotec reaches settlement with Apotex
By IPP Bureau - July 12, 2025
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Hexaware and Abluva join forces to deliver secure Agentic AI solutions for life sciences industry
By IPP Bureau - July 12, 2025
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
Senores Pharmaceuticals to increase stake in Havix
By IPP Bureau - July 12, 2025
Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations
Briefs: Emcure Pharmaceuticals and Gland Pharma
By IPP Bureau - July 12, 2025
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
Indegene launches NEXT Medical Writing Automation
By IPP Bureau - July 12, 2025
To streamline complex medical writing workflows with GenAI
IMCD and Friesland Campina Professional expand distribution agreement across EMEA
By IPP Bureau - July 11, 2025
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
Ichnos Glenmark Innovation announces global commercialization strategy for ISB 2001
By IPP Bureau - July 11, 2025
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Shilpa Medicare Unit VI facility at Dabaspet receives GMP certification from SFDA
By IPP Bureau - July 11, 2025
This was a full GMP inspection of the entire facility with specific focus on Ondansetron Oral Film drug product
Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy
By IPP Bureau - July 11, 2025
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
Bayer submits EU application for Gadoquatrane MRI contrast agent
By IPP Bureau - July 11, 2025
It is intended for contrast enhancement in MRI scans
Apollo AyurVAID launches India’s first ‘Tested Safe’ ayurveda products
By IPP Bureau - July 11, 2025
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
